Two Sigma Advisers’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.94M | Buy |
1,056,779
+131,164
| +14% | +$613K | 0.01% | 748 |
|
|
2025
Q1 | $5.08M | Buy |
925,615
+911,874
| +6,636% | +$5.01M | 0.01% | 786 |
|
|
2024
Q4 | $46.6K | Buy |
+13,741
| New | +$46.6K | ﹤0.01% | 2288 |
|
|
2024
Q3 | – | Sell |
-23,559
| Closed | -$53K | – | 2554 |
|
|
2024
Q2 | $53K | Buy |
23,559
+13,462
| +133% | +$30.3K | ﹤0.01% | 2359 |
|
|
2024
Q1 | $22.3K | Buy |
+10,097
| New | +$22.3K | ﹤0.01% | 2394 |
|
|
2022
Q4 | – | Sell |
-22,100
| Closed | -$34K | – | 2718 |
|
|
2022
Q3 | $34K | Sell |
22,100
-43,700
| -66% | -$67.2K | ﹤0.01% | 2406 |
|
|
2022
Q2 | $101K | Buy |
65,800
+52,900
| +410% | +$81.2K | ﹤0.01% | 2391 |
|
|
2022
Q1 | $33K | Buy |
+12,900
| New | +$33K | ﹤0.01% | 2632 |
|
|
2021
Q3 | – | Sell |
-71,900
| Closed | -$293K | – | 2705 |
|
|
2021
Q2 | $293K | Buy |
71,900
+51,200
| +247% | +$209K | ﹤0.01% | 2151 |
|
|
2021
Q1 | $93K | Buy |
+20,700
| New | +$93K | ﹤0.01% | 2454 |
|
|
2020
Q4 | – | Sell |
-19,900
| Closed | -$118K | – | 2621 |
|
|
2020
Q3 | $118K | Sell |
19,900
-38,400
| -66% | -$228K | ﹤0.01% | 2251 |
|
|
2020
Q2 | $155K | Buy |
58,300
+25,800
| +79% | +$68.6K | ﹤0.01% | 2300 |
|
|
2020
Q1 | $63K | Buy |
+32,500
| New | +$63K | ﹤0.01% | 2360 |
|